Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline : EU signs deal with GSK for supply of potential COVID drug

07/28/2021 | 07:37am EDT
FILE PHOTO: Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility

BRUSSELS (Reuters) - The European Union has signed a contract with GlaxoSmithKline for the supply of up to 220,000 treatments of its investigational monoclonal antibody therapy sotrovimab against COVID-19, it said on Wednesday.

The drug, which is developed together with U.S. firm Vir Biotechnology, can be used for the treatment of high-risk coronavirus patients with mild symptoms who do not require supplemental oxygen, according to the Commission.

The deal is a boost to GSK work on potential treatments for COVID-19 after the company played a limited role in the development of vaccines. Rather than making its own coronavirus shot, GSK has focused on supplying its booster to other developers and has partnered with Sanofi to develop a jab.

GSK confirmed the deal in a statement on Wednesday, saying it represented "a crucial step forward for treating cases of COVID-19" in Europe.

The drug is currently being assessed by the European Medicines Agency (EMA) under a rolling review.

It has received emergency authorisation in the United States to treat mild-to-moderate COVID-19 patients who are at high risk of developing a severe infection.

The contract has been backed by 16 of the 27 EU states, which can buy the drug only after it is approved by EMA or by national drug regulators. The price agreed for potential purchases has not been disclosed. A spokesman for the Commission declined to comment on the matter.

Monoclonal antibodies mimic natural antibodies that the body generates to fight infection.

The deal with GSK follows a contract the EU signed in April with Swiss pharmaceutical giant Roche to secure about 55,000 doses of a potential treatment based on a cocktail of monoclonal antibodies developed by Roche together with U.S. drugmaker Regeneron.

Apart from monoclonal treatments, the only other anti-COVID drug the EU has bought is Gilead's remdesivir, an antiviral medicine. Last year, the EU reserved half a million courses after the drug obtained a conditional EU approval.

(Reporting by Francesco Guarascio with additional reporting by Jo Mason, editing by Louise Heavens and Mark Heinrich)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC -0.49% 1388.2 Delayed Quote.3.44%
VIR BIOTECHNOLOGY, INC. 3.67% 54.54 Delayed Quote.103.66%
All news about GLAXOSMITHKLINE PLC
09/17GLAXOSMITHKLINE : Receives Positive Marketing Recommendation From European Medic..
MT
09/17GLAXOSMITHKLINE : GSK Lands Positive Opinion From European Medicines Agency for ..
MT
09/17GLAXOSMITHKLINE : GSK receives CHMP positive opinions recommending approval of N..
PU
09/15PharmaSGP Holding SE raises forecast for FY 2021 following completion of acqu..
DJ
09/15CROSSWORD CYBERSECURITY PLC : Appointments URENCO CISO to Advisory Board
AQ
09/15CureVac Cancels mRNA Contracts For COVID-19 Jab
MT
09/14GLAXOSMITHKLINE : Deutsche Bank reiterates its Neutral rating
MD
09/13GLAXOSMITHKLINE ( '') (FORM 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)
PU
09/09GLAXOSMITHKLINE ( '') (FORM 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)
PU
09/09FTSE 100 Drops as Pharma, Commodities Fall
DJ
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Financials
Sales 2021 33 309 M 45 759 M 45 759 M
Net income 2021 3 875 M 5 323 M 5 323 M
Net Debt 2021 20 960 M 28 795 M 28 795 M
P/E ratio 2021 18,1x
Yield 2021 5,76%
Capitalization 69 478 M 95 560 M 95 450 M
EV / Sales 2021 2,72x
EV / Sales 2022 2,54x
Nbr of Employees 94 066
Free-Float 92,2%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 1 388,20 GBX
Average target price 1 608,27 GBX
Spread / Average Target 15,9%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC3.44%95 560
JOHNSON & JOHNSON4.68%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.20.81%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.28%209 456